个人简介：

C-level Drug discovery project management and business development.

Senior medicinal chemist with 20 years of drug discovery experience including project leadership and supervisory roles.

Extensive experience in small molecule lead generation, lead optimization and pre-clinical development to IND filing in the oncology and metabolic disease therapeutic arenas.

High level of proficiency in the application of structure-based drug design (SBDD) methodology.

Broad-based background in organic and parallel synthesis with expertise in heterocyclic, peptidomimetic and nucleoside chemistry.

Strong inventorship and publication record.

Technical skill: ENotes, MOE, ISIS Base and lab instruments.

公司简介：

浙江昭华生物医药有限公司（昭华生药，Zova Biotherapeutics Inc.）从美国Concortis公司引入先进的抗体-药物偶联体（Antibody-Drug Conjugates, ADC)类药物的开发技术，立足中国，在全球范围内从事抗体-药物偶联体类新型生物制药的研究、开发、合作、转让和生产。

“昭华生药”力争成为ADC类生物制药领域的创新者和领导者。目前拥有员工数10人，其中博士3人，硕士5人。作为第一个项目，昭华已成功研发出采用化学方法做到定点定量偶联的抗her2靶点ADC – ZV0203，该产品研发已完成三批中试，正在进行毒理安评阶段，很快将完成临床前评价阶段进入临床试验中，其专利也已拿到受理号。在第二个项目上，昭华以在多种恶性肿瘤上均有高表达的5T4为靶向，已通过荷瘤动物模型筛选出有强抗癌活性的ZV0508作为临床前开发的候选ADC。另外，我们还有2个ADC和双靶向的项目也已进入细胞筛选阶段。